COMMUNIQUÉS West-GlobeNewswire

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
27/03/2026
Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not [...]
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
27/03/2026
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer and vascular [...]
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
27/03/2026
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
27/03/2026
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical proof-of-concept [...]
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
27/03/2026
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs , Inc. (Nasdaq: AIDX), an early market [...]
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
27/03/2026
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and [...]
Axe Compute to Host Annual Report Conference Call
27/03/2026
Axe Compute to Report Fiscal Year 2025 Financial Results and File Annual Report on Form 10-K Conference call and webcast scheduled for April 1, 2026 PITTSBURGH, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Axe Compute ( [...]
Precision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock
27/03/2026
GARDNER, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
27/03/2026
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with [...]
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27/03/2026
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond [...]
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
27/03/2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
27/03/2026
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Arletta Pharma Solutions Announces Positive Results from Phase II Clitoral Doppler Duplex Ultrasound Study of Lybrido™ Combination Targeting Female Sexual Dysfunction
27/03/2026
www.arlettapharmasolutions.com More than 60% average improvement in clitoral blood flow observed with both dose-combinations Statistical significance achieved with new high dose-combination despite small sample size [...]
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
27/03/2026
Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ( “ Clearmind ” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
SafeSpace Global to Attend NIC Spring Conference to Engage Senior Living and Healthcare Leaders
27/03/2026
Knoxville, TN., March 27, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
27/03/2026
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical [...]
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
27/03/2026
sNDA submitted seeking approval of IGALMI ® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential [...]
Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple
27/03/2026
La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple Recommandation fondée sur des [...]
Vor Bio Announces $75 Million Private Placement with TCGX
27/03/2026
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase [...]

Pages